BRCA1 and breast cancer: Given that aberrantly lower levels of circulating RANKL have previously been described among women with a BRCA mutation, along with the important role of RANK signaling in BRCA1-breast cancer development, it is necessary to evaluate whether levels of circulating RANKL also predict cancer risk.